Resources
In a pharmacology laboratory, researchers evaluate the therapeutic index () of two antimicrobial agents: Agent X (an antibacterial targeting bacterial DNA gyrase) and Agent Y (an antiviral targeting viral protease). For Agent X, the median toxic dose to human kidney cells is , and the median effective dose against Escherichia coli is . For Agent Y, the median toxic dose to host cells is , and the median effective dose against a retrovirus is . (a) Calculate the therapeutic index () for each agent. (b) Determine the ratio of to . (c) Identify which agent provides a wider margin of safety, and explain this difference based on host-pathogen structural specificity.
Answer and steps
Final answer
(a) For Agent X, ; for Agent Y, . (b) The ratio . (c) Agent X exhibits a significantly wider margin of safety (higher ) because bacterial DNA gyrase is structurally distinct from human topoisomerases, whereas viral replication relies extensively on host cellular machinery, increasing the likelihood of host cell toxicity with antivirals.
Steps
Part (a): Calculating the Therapeutic Index ()
The therapeutic index () represents the safety window of a drug and is defined as: where is the median toxic dose to host cells and is the median effective dose against the pathogen.
- For Agent X (Antibacterial):
- For Agent Y (Antiviral):
Part (b): Determining the Ratio of the Therapeutic Indices
To find the relative margin of safety between the two agents, calculate the ratio of to :
Part (c): Safety Margin and Host-Pathogen Specificity
- Wider Margin of Safety: Agent X possesses a much wider margin of safety than Agent Y because a higher therapeutic index indicates a greater concentration gap between the therapeutic dose and the toxic dose.
-
Biological Basis (Selective Toxicity):
- Prokaryotic vs. Eukaryotic Targets (Agent X): Bacteria are prokaryotic organisms possessing distinct biochemical pathways and enzymes absent or structurally divergent in human eukaryotic cells. Agent X targets bacterial DNA gyrase (a type II topoisomerase). While humans also possess topoisomerases, the subunit structure and binding pockets of bacterial DNA gyrase differ significantly, enabling high selective toxicity without interfering with host enzymes at low doses.
- Intracellular Viral Parasitism (Agent Y): Viruses lack independent metabolic machinery and replicate exclusively inside host cells using host cellular components. Even when an antiviral targets a specific viral protein (such as viral protease), developing drugs that do not partially inhibit or cross-react with structurally related host cellular proteases is difficult. Consequently, antiviral compounds often produce collateral host cell toxicity at lower relative thresholds, yielding a narrower therapeutic window.
Typical errors
01 The student inverts the therapeutic index formula as ED50 / TD50, leading to inverted index values and concluding Agent Y has a wider margin of safety.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1Correct
You inverted the therapeutic index ratio. The therapeutic index is defined as median toxic dose divided by median effective dose (), which yields for Agent X and for Agent Y.
- Step 2Correct
You correctly divided your two calculated indices, but this result was affected by the inverted values from Step 1. Using the correct indices gives a ratio of .
- Step 3
Agent Y provides a wider margin of safety because it has a higher calculated TI value.
CorrectAgent X provides a significantly wider margin of safety because it has a substantially higher therapeutic index ( vs. ).
Your reasoning logically followed your inverted numerical calculations, but because the actual therapeutic index of Agent X () is much larger than that of Agent Y (), Agent X actually provides the wider safety margin.
- Step 4
Viruses have higher mutation rates, so host cells develop specific immune mechanisms that tolerate the drug better than bacterial targets.
CorrectAgent X achieves a higher margin of safety because bacterial DNA gyrase is a prokaryotic target distinct from host topoisomerases (high selective toxicity). In contrast, viruses replicate obligately inside host cells using host cellular machinery, making it harder to target viral components without collateral toxicity to the host.
The safety margin of an antimicrobial drug depends on selective toxicity between the pathogen and host cells, not viral mutation rates or host immune drug tolerance. Bacteria have distinct prokaryotic structures (like DNA gyrase) absent or structurally divergent in human cells, whereas viruses depend heavily on host cellular machinery.
WHAT YOU DID WELL
Compliments from Your TeacherYou correctly identified the relevant numerical values for toxic dose and effective dose from the prompt.
You accurately carried out the arithmetic for your chosen formulas.
You recognized that a larger therapeutic index value corresponds to a wider margin of safety.
THE ERROR
Where Your ACEpath Teacher Spotted the MistakeYou set up the therapeutic index upside down as toxic dose in the denominator rather than the numerator.
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou confused the directionality of drug safety metrics (remembering that low effective dose and high toxic dose are desirable, but misplacing them in the ratio) and linked safety margins to viral mutability rather than the concept of selective toxicity between prokaryotic and eukaryotic cellular structures.
REASONING PATH
Your ACEpath teacher’s suggested approach- Therapeutic Index Formula
Always verify that the toxic dose is in the numerator and the effective dose is in the denominator, so a safer drug produces a larger number.
- Structural Selective Toxicity
Drugs targeting unique prokaryotic structures (e.g., bacterial cell walls, bacterial DNA gyrase) have higher selective toxicity than drugs targeting viral components that share or exploit host cellular mechanisms.
When comparing margins of safety between antibacterials and antivirals, explain whether the drug target is unique to the pathogen or shared with host cell machinery.
CORRECTED PATH
ACEpath Teacher's DemonstrationApply the standard formula: and .
Compute the ratio: .
Identify Agent X as having the wider margin of safety because .
Explain that Agent X targets bacterial DNA gyrase, a prokaryotic enzyme with distinct structural differences from human topoisomerases, conferring high selective toxicity. In contrast, Agent Y targets viral processes that occur intracellularly and closely interact with host proteases/cellular machinery, leading to greater risk of host toxicity and a narrower safety margin.
(a) , ; (b) Ratio ; (c) Agent X provides the wider margin of safety due to high selective toxicity against prokaryote-specific bacterial DNA gyrase compared to host-dependent viral replication.
02 The student confuses the relationship between therapeutic index and safety margin, assuming a lower TI means less drug is needed and is therefore safer.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1
- Step 2
- Step 3
Agent Y provides a wider margin of safety because a lower TI indicates higher potency and less toxicity to tissues.
CorrectAgent X provides a significantly wider margin of safety because a higher therapeutic index indicates a much larger gap between the effective dose and the toxic dose.
You concluded that Agent Y is safer because of its lower , but means that a larger value represents a wider gap between the effective dose and the toxic dose.
- Step 4
Agent Y targets viral protease which is much smaller than bacterial enzymes, allowing lower non-specific damage to human cells.
CorrectAgent X exhibits greater selective toxicity because bacterial DNA gyrase is structurally distinct from eukaryotic topoisomerases. In contrast, viruses replicate inside host cells using host cellular machinery, so antiviral agents carry a higher risk of collateral toxicity to host enzymes.
Target size does not determine selective toxicity; rather, antibacterial agents generally have higher safety margins because prokaryotes possess distinct metabolic pathways and unique enzyme structures, whereas obligate intracellular viruses rely heavily on host cell machinery.
WHAT YOU DID WELL
Compliments from Your TeacherYou correctly used the therapeutic index formula to calculate the values for both antimicrobial agents.
You computed the exact mathematical ratio between the two indices accurately.
THE ERROR
Where Your ACEpath Teacher Spotted the MistakeYou treated a lower therapeutic index as an indicator of safety, confusing low dosage requirement with a wide safety window.
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou conflated clinical potency (low ) with the therapeutic window (), and you evaluated selective toxicity by molecular size rather than evolutionary divergence between host and pathogen targets.
REASONING PATH
Your ACEpath teacher’s suggested approach- Interpreting Therapeutic Index
; because toxic dose is in the numerator, a larger signifies that a much higher dose is required to produce toxicity relative to the therapeutic dose.
Always associate a higher with a safer drug and a wider therapeutic window.
- Selective Toxicity in Pathogens
Antibiotics generally exhibit higher selective toxicity because prokaryotic structures (like peptidoglycan cell walls or bacterial DNA gyrase) differ markedly from eukaryotic host cells. Antivirals face greater challenges because viruses rely on host cellular enzymes to replicate.
Explain differences in selective toxicity by citing unique prokaryotic vs. eukaryotic structures, not enzyme size.
CORRECTED PATH
ACEpath Teacher's DemonstrationCompare the computed values: and . Because , Agent X has an eightfold larger safety margin.
Relate the safety margin to target biology: Agent X targets bacterial DNA gyrase, an enzyme with subunit architecture and binding sites unique to prokaryotes, minimizing cross-reactivity with human topoisomerases.
Contrast with viral targets: Agent Y targets a viral protease during intracellular replication, where similarity to host proteases and dependency on host cellular mechanisms make collateral host toxicity more likely.
Agent X provides a wider margin of safety because its higher ( vs. ) indicates a larger separation between toxic and effective doses. Biologically, bacterial DNA gyrase is structurally distinct from eukaryotic host enzymes, whereas viruses rely extensively on host cell machinery, making selective toxicity harder to achieve without host toxicity.
03 The student calculates the ratio in reverse as TI(Agent Y) / TI(Agent X) instead of TI(Agent X) / TI(Agent Y).
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1
- Step 2Correct
The prompt asked for the ratio of to , which means belongs in the numerator and in the denominator.
- Step 3
Agent X provides a wider margin of safety because it has a higher TI value of 260. Agent X targets bacterial DNA gyrase which is absent in human cells, whereas Agent Y targets viral proteases that overlap with host cellular proteases.
WHAT YOU DID WELL
Compliments from Your TeacherYou correctly calculated the therapeutic index for both compounds.
You correctly concluded that Agent X has a wider margin of safety due to its higher therapeutic index.
You provided a strong biological rationale comparing bacterial DNA gyrase with host cellular machinery.
THE ERROR
Where Your ACEpath Teacher Spotted the MistakeYou set up the ratio upside down as rather than .
WHY IT HAPPENED
ACEpath Teacher's DiagnosisIn verbal problem statements of the form 'ratio of A to B', the first quantity mentioned () is always the numerator and the second () is the denominator. Reversing their positions produces the reciprocal instead of the requested ratio.
REASONING PATH
Your ACEpath teacher’s suggested approach- Translating 'Ratio of A to B'
The phrase 'ratio of to ' mathematically translates to .
Always write down the algebraic formula with labels before substituting numerical values.
CORRECTED PATH
ACEpath Teacher's DemonstrationIdentify the terms in the requested ratio: numerator is , and denominator is .
Compute the quotient: .
Lock it in
What is the formula for the therapeutic index () of a drug, and does a safer drug have a higher or lower ?
(or ). A safer drug has a higher because toxic dose is much greater than effective dose (mnemonic: 'Toxic on Top').
Similar question
An antifungal compound has an effective dose and a toxic dose . Calculate its therapeutic index () and state whether a drug with would be safer or less safe.
Answer
. A drug with would be safer because a higher therapeutic index indicates a wider margin of safety between the therapeutic dose and toxic dose.
Drug A inhibits bacterial cell wall synthesis with and . Drug B inhibits viral RNA-dependent RNA polymerase with and . Calculate the ratio of to and identify which drug has a narrower safety window.
Answer
For Drug A, . For Drug B, . The ratio is . Drug B has the narrower safety window because its therapeutic index is significantly smaller ().
Penicillin targets bacterial transpeptidase (involved in peptidoglycan synthesis) and has a . Acyclovir targets viral thymidine kinase and has a moderate . Amphotericin B targets fungal ergosterol, which closely resembles mammalian cholesterol, yielding a very low . Explain how evolutionary divergence of the drug target relative to human host cell structures explains this trend across the three antimicrobial classes.
Answer
Selective toxicity is directly determined by the biochemical divergence between the pathogen target and host cell structures. Penicillin has the highest because peptidoglycan cell walls are completely absent in human cells (prokaryotic-specific target). Acyclovir has an intermediate because while viral thymidine kinase provides selective activation, viral replication relies closely on host cellular machinery. Amphotericin B has the lowest because fungi are eukaryotic and ergosterol shares high structural homology with human membrane cholesterol, leading to frequent off-target binding and substantial host cell cytotoxicity.